$IMNM
Immunome Inc

2023 Q2 Form 10-Q Financial Statement

#000155837023008194 Filed on May 05, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $4.263M $2.364M
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.362M $2.963M
YoY Change 35.93% -17.14%
% of Gross Profit
Research & Development $5.716M $3.913M
YoY Change -0.02% -51.56%
% of Gross Profit
Depreciation & Amortization $101.0K $94.00K
YoY Change -10.62% -15.32%
% of Gross Profit
Operating Expenses $10.04M $6.835M
YoY Change 12.44% -41.35%
Operating Profit -$5.773M -$4.471M
YoY Change -35.32% -61.64%
Interest Expense $216.0K $201.0K
YoY Change 10700.0% 20000.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$5.557M -$4.270M
YoY Change -37.73% -63.36%
Income Tax
% Of Pretax Income
Net Earnings -$5.557M -$4.300M
YoY Change -37.73% -63.25%
Net Earnings / Revenue -130.35% -181.9%
Basic Earnings Per Share -$0.46 -$0.35
Diluted Earnings Per Share -$0.46 -$0.35
COMMON SHARES
Basic Shares Outstanding 12.22M 12.22M
Diluted Shares Outstanding 12.20M 12.18M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $38.42M $44.42M
YoY Change 10.87% 3.6%
Cash & Equivalents $38.42M $44.42M
Short-Term Investments
Other Short-Term Assets $902.0K $1.291M
YoY Change -69.41% -50.89%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $39.53M $46.54M
YoY Change 5.13% 0.5%
LONG-TERM ASSETS
Property, Plant & Equipment $1.203M $916.0K
YoY Change 49.07% 21.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $532.0K $432.0K
YoY Change 23.15% -10.37%
Total Long-Term Assets $1.909M $1.578M
YoY Change 34.34% 10.74%
TOTAL ASSETS
Total Short-Term Assets $39.53M $46.54M
Total Long-Term Assets $1.909M $1.578M
Total Assets $41.44M $48.11M
YoY Change 6.19% 0.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.699M $3.310M
YoY Change -29.66% -14.91%
Accrued Expenses $5.025M $3.306M
YoY Change 49.6% -43.17%
Deferred Revenue $17.67M $18.22M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change
Total Short-Term Liabilities $26.39M $24.83M
YoY Change 206.24% 155.81%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $9.421M
YoY Change 6308.84%
Total Long-Term Liabilities $0.00 $9.421M
YoY Change -100.0% 6308.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.39M $24.83M
Total Long-Term Liabilities $0.00 $9.421M
Total Liabilities $32.10M $34.25M
YoY Change 267.16% 247.59%
SHAREHOLDERS EQUITY
Retained Earnings -$125.8M -$120.3M
YoY Change 26.18% 32.49%
Common Stock $1.000K $1.000K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.338M $13.86M
YoY Change
Total Liabilities & Shareholders Equity $41.44M $48.11M
YoY Change 6.19% 0.81%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$5.557M -$4.300M
YoY Change -37.73% -63.25%
Depreciation, Depletion And Amortization $101.0K $94.00K
YoY Change -10.62% -15.32%
Cash From Operating Activities -$5.668M $24.17M
YoY Change -29.68% -479.12%
INVESTING ACTIVITIES
Capital Expenditures $340.0K $106.0K
YoY Change -300.0% 1666.67%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$340.0K -$106.0K
YoY Change 100.0% 1666.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 34.00K
YoY Change 6.25%
NET CHANGE
Cash From Operating Activities -5.668M 24.17M
Cash From Investing Activities -340.0K -106.0K
Cash From Financing Activities 0.000 34.00K
Net Change In Cash -6.008M 24.10M
YoY Change -27.0% -479.54%
FREE CASH FLOW
Cash From Operating Activities -$5.668M $24.17M
Capital Expenditures $340.0K $106.0K
Free Cash Flow -$6.008M $24.07M
YoY Change -23.85% -477.11%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3576000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
6835000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
34000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12182478
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12122903
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001472012
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12194184
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12128843
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39580
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Immunome, Inc
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0694340
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
665 Stockton Drive
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Exton
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19341
CY2023Q1 dei City Area Code
CityAreaCode
610
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
321-3700
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
CY2023Q1 dei Trading Symbol
TradingSymbol
IMNM
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12215018
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44424000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20323000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2112000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2326000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
46536000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
22649000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
916000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
681000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
230000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
284000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2023Q1 us-gaap Deferred Costs
DeferredCosts
332000
CY2022Q4 us-gaap Deferred Costs
DeferredCosts
332000
CY2023Q1 us-gaap Assets
Assets
48114000
CY2022Q4 us-gaap Assets
Assets
24046000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3310000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2400000
CY2023Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
3306000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
4931000
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
18215000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
24831000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7331000
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
9421000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
62000
CY2023Q1 us-gaap Liabilities
Liabilities
34252000
CY2022Q4 us-gaap Liabilities
Liabilities
7393000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12194184
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12128843
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
134132000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
132653000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-120271000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116001000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
13862000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
16653000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
48114000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24046000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2364000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3913000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8078000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2922000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
11654000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4471000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11654000
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
201000
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4270000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11653000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12182478
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12122903
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
16653000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1200000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
221000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
24000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4270000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
13862000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
48185000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1310000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
32000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11653000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
37874000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-4270000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-11653000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
94000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
111000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
54000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
25000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1224000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1310000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-214000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3973000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
687000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
788000
CY2023Q1 imnm Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-1404000
CY2022Q1 imnm Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-912000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
27636000
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-62000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-18000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
24173000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6376000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
106000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-106000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
24101000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6350000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20423000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49329000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44524000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42979000
CY2023Q1 us-gaap Stock Issued1
StockIssued1
221000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
223000
CY2022Q1 imnm Stock Issuance Costs Included In Accounts Payable And Accrued Expenses And Other Liabilities Current
StockIssuanceCostsIncludedInAccountsPayableAndAccruedExpensesAndOtherLiabilitiesCurrent
25000
CY2022Q1 imnm Offering Cost In Accounts Payable
OfferingCostInAccountsPayable
25000
CY2022Q1 imnm Capital Expenditures Incurred But Not Yet Paid Included In Accrued Expenses And Other Current Liabilities
CapitalExpendituresIncurredButNotYetPaidIncludedInAccruedExpensesAndOtherCurrentLiabilities
3000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4300000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11700000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-120300000
CY2023Q1 imnm Proceeds From Issuance Of Equity And Debt
ProceedsFromIssuanceOfEquityAndDebt
155100000
CY2022 imnm Reimbursement Received
ReimbursementReceived
17600000
CY2021Q4 imnm Shares Authorized For Issuance Amount
SharesAuthorizedForIssuanceAmount
200000000.0
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44400000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these condensed financial statements include, but are not limited to, the expected volatility used to estimate fair value of stock options, accrued research and development expenses, and the estimated costs which drive the revenue recognition for the Collaboration Agreement with AbbVie. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Estimates and assumptions are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from these estimates.</p>
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44424000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42879000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
100000
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
100000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44524000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42979000
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Concentration of credit risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in a financial institution in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at a financial institution that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits. </p>
CY2023Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
300000
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
300000
CY2022Q4 imnm Prepaid Subscriptions Prepaid Service Contracts And Short Term Deposits
PrepaidSubscriptionsPrepaidServiceContractsAndShortTermDeposits
876000
CY2023Q1 imnm Research And Development Expense Advance Payments
ResearchAndDevelopmentExpenseAdvancePayments
271000
CY2022Q4 imnm Research And Development Expense Advance Payments
ResearchAndDevelopmentExpenseAdvancePayments
445000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3817356
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3312956
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
253000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
158000
CY2023Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
71000
CY2022Q1 imnm Contra Research And Development Expense
ContraResearchAndDevelopmentExpense
600000
CY2020Q1 imnm Refundable Employee Retention Credit
RefundableEmployeeRetentionCredit
800000
CY2023Q1 imnm Employee Retention Credit Receivable
EmployeeRetentionCreditReceivable
800000
CY2023Q1 imnm Employee Retention Credit Receivable
EmployeeRetentionCreditReceivable
821000
CY2022Q4 imnm Employee Retention Credit Receivable
EmployeeRetentionCreditReceivable
847000
CY2023Q1 imnm Prepaid Subscriptions Prepaid Service Contracts And Short Term Deposits
PrepaidSubscriptionsPrepaidServiceContractsAndShortTermDeposits
696000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2112000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2326000
CY2023Q1 imnm Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1993000
CY2022Q4 imnm Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2261000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
827000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1874000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
236000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
293000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
250000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
481000
CY2022Q4 imnm Deferred Research Obligations Liabilities Current
DeferredResearchObligationsLiabilitiesCurrent
22000
CY2023Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
3306000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
4931000
CY2022Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
CY2023Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
CY2023Q1 imnm Collaborative Arrangements Product Development And Regulatory Approval Milestone Payments Payable
CollaborativeArrangementsProductDevelopmentAndRegulatoryApprovalMilestonePaymentsPayable
2600000
CY2023Q1 imnm Collaborative Arrangements Commercial Milestone Payments Payable
CollaborativeArrangementsCommercialMilestonePaymentsPayable
1500000
CY2023Q1 imnm Common Stock Voting Right
CommonStockVotingRight
1
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1224000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1310000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
7600000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.879
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.835
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.039
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M15D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2023Q1 imnm Fair Value Of Common Stock
FairValueOfCommonStock
5.39
CY2022Q1 imnm Fair Value Of Common Stock
FairValueOfCommonStock
10.58
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2519405
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.60
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
29100
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.39
CY2023Q1 imnm Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm
P9Y10M17D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
54293
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.03
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
802
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
13.79
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2493410
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.50
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M18D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1368315
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.19
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y10M28D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.18
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.52
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2900000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4200000

Files In Submission

Name View Source Status
0001558370-23-008194-index-headers.html Edgar Link pending
0001558370-23-008194-index.html Edgar Link pending
0001558370-23-008194.txt Edgar Link pending
0001558370-23-008194-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20230331.xsd Edgar Link pending
tmb-20230331x10q.htm Edgar Link pending
tmb-20230331xex31d1.htm Edgar Link pending
tmb-20230331xex31d2.htm Edgar Link pending
tmb-20230331xex32d1.htm Edgar Link pending
tmb-20230331xex32d2.htm Edgar Link pending
tmb-20230331_cal.xml Edgar Link unprocessable
tmb-20230331_def.xml Edgar Link unprocessable
tmb-20230331_lab.xml Edgar Link unprocessable
tmb-20230331_pre.xml Edgar Link unprocessable
tmb-20230331x10q_htm.xml Edgar Link completed